Elicera announces outcome of the rights issue
Summary
Elicera Therapeutics has completed the outcome of its rights issue and secured about SEK 54.6 million before transaction costs. Investors subscribed for about 36.3% of the offered shares directly, and guarantors will cover the remainder up to the agreed 75% commitment level. The company plans to use the proceeds to finish its CARMA study and accelerate preparation for its planned Phase I/Ib trial of ELC-401 in glioblastoma. Trading in the new shares on Nasdaq First North Growth Market is expected to begin around June 10, 2026.
Funding
Amount
$5
Total raised
Date
June 1, 2026
Announcement date
Investors
-
Lead investors
Company
elicera.com
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected